Early-Stage trial for Ultra-Rare cancer halted
NCT ID NCT04204941
Summary
This early-stage trial tested whether adding a new drug, tazemetostat, to a standard chemotherapy (doxorubicin) was safe and could help control an ultra-rare and aggressive cancer called epithelioid sarcoma. The study was small and ended early, so it only gathered initial safety information and did not complete its main goal of testing if the combination helped patients live longer without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Insititute
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fred Hutchinson Research Center
Seattle, Washington, 98109, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
-
Mayo Clinic-Jacksonville
Jacksonville, Florida, 32224, United States
-
McGill University Faculty of Medicine - Royal Victoria Hospital
Montreal, Quebec, H4A 3J1, Canada
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Royal Marsden Foundation Trust
London, SW3 6JJ, United Kingdom
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
-
Sarah Cannon and HCA Research Institute
Nashville, Tennessee, 37203, United States
-
Sarcoma Oncology Research Center
Santa Monica, California, 90403, United States
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado, 80045, United States
-
University of Michigan Medical Center
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh Medical Center - Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Washington University
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.